Patents Assigned to University of Vermont
-
Patent number: 11990750Abstract: Demand response methodologies for primary frequency response (PFR) for under or over frequency events. Aspects of the present disclosure include methods for controlling a fleet of distributed energy resources equipped for PFR and quantifying in real time an amount of primary frequency control capacity available in the fleet. In some examples, the DERs may be configured to consume and discharge electrical energy in discrete energy packets and be equipped with a frequency response local control law that causes each DER to independently and instantaneously interrupt an energy packet in response to local frequency measurements indicating a grid disturbance event has occurred.Type: GrantFiled: July 8, 2021Date of Patent: May 21, 2024Assignee: University of Vermont and State Agricultural CollegeInventors: Mads Almassalkhi, Hani Mavalizadeh, Luis A. Duffaut Espinosa
-
Patent number: 11976330Abstract: Methods and kits for detecting cancer-associated miRNA are disclosed herein. Methods of identifying and treating a human patient at risk for cancer are also disclosed herein.Type: GrantFiled: April 6, 2018Date of Patent: May 7, 2024Assignee: The University of Vermont and State Agricultural CollegeInventors: Marie E. Wood, Jane B. Lian, Nicholas Farina, Janet L. Stein
-
Patent number: 11883395Abstract: Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.Type: GrantFiled: May 13, 2021Date of Patent: January 30, 2024Assignee: The University of Vermont and State Agricultural CollegeInventors: Vikas Anathy, Nicolas Chamberlain, Amit Kumar
-
Patent number: 11878997Abstract: This invention relates to methods of administering compounds containing selenium, selenocysteine, or a selenocysteine peptide to treat, for example, conditions associated with selenium deficiency, or ferroptoptic, parthanototic, and endoplasmic reticulum stress, and/or cancer. The methods of treatment may activate or inhibit (via TFAP2C and Sp1 proteins) the adaptive homeostatic response of the selenome. The compounds may contain a targeting sequence that causes them to be delivered to specific organs and/or tissues. The compounds may be administered, for example, orally, intranasally, intravenously, or by a minimally invasive catheter or BrainPath.Type: GrantFiled: June 30, 2021Date of Patent: January 23, 2024Assignees: Burke Neurological Institute, University of Vermont and State Agricultural CollegeInventors: Rajiv R. Ratan, Ishraq Alim, Saravanan Karuppagounder, Robert Hondal
-
Patent number: 11878276Abstract: A nanobiocatalytic membrane for a filtration system is provided which includes a filtration membrane and a plurality of nanobiocatalyst nanoparticles associated with the membrane, each of the nanobiocatalyst nanoparticles including a core, a coating at least partially surrounding the core, and a plurality of nanobiocatalysts coupled to the coating. Each of the plurality of nanobiocatalysts includes an antibacterial nanoparticle comprising bismuth, and a quorum quenching agent coupled to the antibacterial nanoparticle. A nanobiocatalyst nanoparticle for use with a water purification system is also provided. A method of forming a nanobiocatalytic membrane for a filtration system and a method of using a nanobiocatalytic membrane in a filtration system are also provided.Type: GrantFiled: February 2, 2022Date of Patent: January 23, 2024Assignee: University of Vermont and State Agricultural CollegeInventors: Appala Raju Badireddy, Huijie Lu
-
Publication number: 20230285507Abstract: The invention features compositions featuring (a) one or more of connective tissue growth factor (CTGF) and human C-terminal CTGF peptide; and (b) one or more of insulin and IGF-1; and methods of using such compositions to reduce cardiac tissue damage associated with an ischemic event or to enhance engraftment of a cell in a cardiac tissue.Type: ApplicationFiled: January 25, 2023Publication date: September 14, 2023Applicant: The University of Vermont and State Agriculture CollegeInventor: Jeffrey SPEES
-
Patent number: 11752193Abstract: The invention relates, in part, to methods and compositions that are useful to modulate metabolic function of cells in vivo or in vitro. In some aspects the invention includes methods and/or compositions that increase metabolism in cells, tissues, organs, and/or subjects. In certain aspects the invention includes methods and/or compositions useful to decrease metabolism in cells, tissues, organs, and/or in subjects.Type: GrantFiled: October 2, 2020Date of Patent: September 12, 2023Assignee: University of Vermont and State Agricultural CollegeInventors: Mercedes Rincon, Ketki M. Hatle
-
Patent number: 11747335Abstract: Compositions and methods are provided for determining platelet reactivity where the levels of Fc?RIIa on the surface of platelets is measured and if the levels of Fc?RIIa are greater than a reference value, the platelets have enhanced reactivity.Type: GrantFiled: October 30, 2019Date of Patent: September 5, 2023Assignee: University of Vermont And State Agriculture CollegeInventor: David Schneider
-
Patent number: 11719696Abstract: The invention includes, in part, methods and compounds for diagnosing diseases and conditions characterized by altered threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is altered. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess onset, progression, and/or regression of a disease or condition associated with altered TARS activity.Type: GrantFiled: October 11, 2020Date of Patent: August 8, 2023Assignee: The University of Vermont and State Agricultural CollegeInventors: Christopher Francklyn, Karen M. Lounsbury, Tamara Williams
-
Patent number: 11576949Abstract: The invention features compositions featuring (a) one or more of connective tissue growth factor (CTGF) and human C-terminal CTGF peptide; and (b) one or more of insulin and IGF-1; and methods of using such compositions to reduce cardiac tissue damage associated with an ischemic event or to enhance engraftment of a cell in a cardiac tissue.Type: GrantFiled: April 24, 2020Date of Patent: February 14, 2023Assignee: The University of Vermont and State Agriculture CollegeInventor: Jeffrey Spees
-
Patent number: 11571160Abstract: A system that executes a process for mapping cardiac fibrillation and optimizing ablation treatments. The process, in some embodiments, includes: positioning a two dimensional electrode array to several locations in a patient's heart and at each location, obtaining a conduction velocity and a cycle length measurement from at least two local signals in response to electrical activity in the cardiac tissue. In some embodiments, a regional wavelength is calculated by multiplying the local conduction velocity with the local minimum cycle length. The system can then create a wavelength distribution map that identifies the location of the drivers in the heart. In certain embodiments, the system uses variability of conduction velocity and cycle length in an area to determine the driver type. In some embodiments, the system calculates average distance of drivers to non-conductive tissue boundaries. The system then selects ablation placements that maximize treatment efficacy while minimizing tissue damage.Type: GrantFiled: November 27, 2019Date of Patent: February 7, 2023Assignee: UNIVERSITY OF VERMONTInventor: Peter S. Spector
-
Publication number: 20230009323Abstract: Cryptosporidium is a leading contributor to early childhood mortality, and fully effective treatment for this important infectious disease is lacking. A bicyclic azetidine compound series is disclosed having potent in vitro activity against all C. parvum isolates tested, comparable potencies against C. hominis and C. parvum, and cured cryptosporidiosis in highly susceptible immunosuppressed mice with once-daily dosing.Type: ApplicationFiled: October 23, 2020Publication date: January 12, 2023Applicants: The Broad Institute, Inc., President and Fellows of Harvard College, The University of Vermont and State Agriculture CollegeInventors: Eamon COMER, Bruno MELILLO, Christopher D. HUSTON
-
Publication number: 20220252594Abstract: Provided herein are compositions and methods relating to ?? T cells. Specifically, methods of screening samples for human ?? T cells surface ligands using a soluble human ?? T cell receptor tetramer are provided. Such ligands may be useful in the treatment of diseases, for example, cancer.Type: ApplicationFiled: May 27, 2020Publication date: August 11, 2022Applicant: The University of Vermont and State Agricultural CollegeInventors: Ralph C. Budd, Cheryl Collins
-
Publication number: 20220248939Abstract: Techniques for operating and monitoring an endoscopic balloon dilation system.Type: ApplicationFiled: May 15, 2020Publication date: August 11, 2022Applicant: The University of Vermont and State Agricultural CollegeInventors: Richard Zubarik, Silas Hill
-
Publication number: 20220215536Abstract: Techniques for diagnosing a patient having an AAA. The techniques include using a computer hardware processor to perform: accessing computed tomography angiography (CTA) images of a portion of the patient, the portion of the patient including the AAA of the patient; providing the CTA images as input to a trained machine learning model, the trained machine learning model being configured to classify a property of the AAA based on the CTA images; and determining, based on the classified property of the AAA, a diagnosis of the patient, the diagnosis including information identifying at least one condition (e.g., an endoleak, an AAA rupture) of the patient.Type: ApplicationFiled: April 8, 2020Publication date: July 7, 2022Applicant: The University of Vermont and State Agricultural CollegeInventors: Daniel Bertges, Safwan Wshah, Christopher S. Morris, Sage Hahn
-
Publication number: 20220203100Abstract: According to some aspects, a cardiac pacemaker for implantation within a subject is provided, the pacemaker including a housing, at least one sensor configured to detect an activity level of the subject, and at least one processor coupled to the sensor configured to detect inactivity of the subject based on output from the at least one sensor, produce a first signal configured to increase the heart rate of the subject to a first heart rate during a first time period, wherein the first heart rate is above a resting heart rate and below 100 beats per minute, and in response to determining that the first time period has elapsed, producing a second signal configured to increase the heart rate of the subject to a second heart rate during a second time period, wherein the second heart rate is between 100 and 140 beats per minute.Type: ApplicationFiled: February 4, 2022Publication date: June 30, 2022Applicant: The University of Vermont and State Agricultural CollegeInventor: Markus Meyer
-
Publication number: 20220169746Abstract: Compositions and methods involving anti-neoantigen antibodies and/or effector cells armed with anti-neoantigen antibodies are disclosed herein. Such compositions may also include immune checkpoint inhibitors and may be used, for example, in the treatment of cancers.Type: ApplicationFiled: February 26, 2020Publication date: June 2, 2022Applicant: The University of Vermont and State Agricultural CollegeInventors: David N. Krag, Girja S. Shukla, Stephanie C. Fournier, Sunny Yujing Sun
-
Patent number: 11340227Abstract: The invention includes, in part, methods and compounds for diagnosing diseases and conditions characterized by altered threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is altered. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess onset, progression, and/or regression of a disease or condition associated with altered TARS activity.Type: GrantFiled: November 28, 2018Date of Patent: May 24, 2022Assignee: University of Vermont and State Agricultural CollegeInventors: Christopher Francklyn, Karen M. Lounsbury, Tamara Williams
-
Patent number: 11331415Abstract: The present invention relates to the unexpected discovery of novel hydrogel formulations that allow for the encapsulation and delivery of living cells and/or drugs to a subject in need thereof. In certain embodiments, the hydrogel compositions of the invention comprise bound bioactive molecules that promote long-term cell viability and allows for the development of vasculature. The invention further provides methods of delivering viable cells and/or drugs to a subject comprising administering the compositions of the invention to the subject in need thereof.Type: GrantFiled: April 11, 2019Date of Patent: May 17, 2022Assignee: UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGEInventors: Rachael A. Oldinski, Jennifer N. Etter
-
Publication number: 20220125762Abstract: The invention relates to compounds that demonstrate efficacy in blocking PACAP receptors (e.g. PAC1) and associated methods of treating neurological diseases or disorders using the disclosed compounds. The neurological diseases or disorders include, but are not limited to, stress-related diseases (e.g. chronic stress, post-traumatic stress disorder (PTSD), anxiety, or general anxiety disorder), pain-related diseases (e.g. chronic pain, primary headache disorders, or migraines), or addiction (e.g. addiction to a substance (e.g. addiction to cocaine, amphetamines, methamphetamine, methylphenidate, nicotine, alcohol, prescription medication, marijuana, tobacco, or an opioid selected from heroin, fentanyl, codeine, hydrocodone, morphine, oxycodone, hydromorphone, and methadone)).Type: ApplicationFiled: February 13, 2020Publication date: April 28, 2022Applicant: The University of Vermont and State Agricultural CollegeInventors: Victor May, Matthias Brewer, Jianing Li